Transcatheter Edge-to-Edge Repair in Patients With Anatomically Complex Degenerative Mitral Regurgitation

  • Jörg Hausleiter
  • D Scott Lim
  • Linda D Gillam
  • Firas Zahr
  • Scott Chadderdon
  • Andrew N Rassi
  • Raj Makkar
  • Scott Goldman
  • Volker Rudolph
  • James Hermiller
  • Robert M Kipperman
  • Abhijeet Dhoble
  • Richard Smalling
  • Azeem Latib
  • Susheel K Kodali
  • Mohamad Lazkani
  • Joseph Choo
  • Philipp Lurz
  • William W O'Neill
  • Roger Laham
  • Josep Rodés-Cabau
  • Saibal Kar
  • Niklas Schofer
  • Brian Whisenant
  • Ignacio Inglessis-Azuaje
  • Stephan Baldus
  • Samir Kapadia
  • Konstantinos Koulogiannis
  • Leo Marcoff
  • Robert L Smith
  • PASCAL IID Registry Investigators

Related Research units

Abstract

BACKGROUND: Mitral valve transcatheter edge-to-edge repair is safe and effective in treating degenerative mitral regurgitation (DMR) patients at prohibitive surgical risk, but outcomes in complex mitral valve anatomy patients vary.

OBJECTIVES: The PASCAL IID registry assessed safety, echocardiographic, and clinical outcomes with the PASCAL system in prohibitive risk patients with significant symptomatic DMR and complex mitral valve anatomy.

METHODS: Patients in the prospective, multicenter, single-arm registry had 3+ or 4+ DMR, were at prohibitive surgical risk, presented with complex anatomic features based on the MitraClip instructions for use, and were deemed suitable for the PASCAL system by a central screening committee. Enrolled patients were treated with the PASCAL system. Safety, effectiveness, and functional and quality-of-life outcomes were assessed. Study oversight also included an echocardiographic core laboratory and clinical events committee.

RESULTS: The study enrolled 98 patients (37.2% ≥2 independent significant jets, 15.0% severe bileaflet/multi scallop prolapse, 13.3% mitral valve orifice area <4.0 cm2, and 10.6% large flail gap and/or large flail width). The implant success rate was 92.9%. The 30-day composite major adverse event rate was 11.2%. At 6 months, 92.4% patients achieved MR ≤2+ and 56.1% achieved MR ≤1+ (P < 0.001 vs baseline). The Kaplan-Meier estimates for survival, freedom from major adverse events, and heart failure hospitalization at 6 months were 93.7%, 85.6%, and 92.6%, respectively. Patients experienced significant symptomatic improvement compared with baseline (P < 0.001).

CONCLUSIONS: The outcomes of the PASCAL IID registry establish the PASCAL system as a useful therapy for prohibitive surgical risk DMR patients with complex mitral valve anatomy. (PASCAL IID Registry within the Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial [CLASP IID] NCT03706833).

Bibliographical data

Original languageEnglish
ISSN0735-1097
DOIs
Publication statusPublished - 07.02.2023

Comment Deanary

Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

PubMed 36725171